Leap therapeutics reports initial clinical data from part b of the defiance study and part c of the distinguish study

35% objective response rate (orr) in second-line colorectal cancer (crc) patients treated with sirexatamab (dkn-01) plus bevacizumab and chemotherapy, compared to 23% orr in the control arm dkk1 levels highly correlated with clinical activity in crc population orr benefit with sirexatamab observed across multiple potential phase 3 crc populations preparations will begin for a registrational phase 3 study in second-line crc patients distinguish part c study in gastric cancer demonstrates activity in biomarker populations,  but not the signal necessary to advance into phase 3 leap to host a conference call to present clinical data today, january 28, 2025, at 8:00 a.m. et cambridge, mass.
LPTX Ratings Summary
LPTX Quant Ranking